Plasmodium falciparum and Plasmodium vivax, the two protozoan parasite species that
cause the majority of cases of human malaria, have developed resistance to nearly all …

Background Artemisinin combination therapy (ACT) is recommended as first-line treatment
for uncomplicated Plasmodium falciparum malaria, whereas chloroquine is still commonly …

In regions with high malaria endemicity, the withdrawal of chloroquine (CQ) as first-line
treatment of Plasmodium falciparum infections has typically led to the restoration of CQ …

Background Recent efforts in malaria control have resulted in great gains in reducing the
burden of Plasmodium falciparum, but P. vivax has been more refractory. Its ability to form …

Abstract The Horn of Africa harbors the largest reservoir of Plasmodium vivax in the
continent. Most of sub-Saharan Africa has remained relatively vivax-free due to a high …

Since 2000, the world has made significant progress in reducing malaria morbidity and
mortality, and several countries in Africa, South America and South‐East Asia are working …

One of the fundamental steps toward malaria control is the use of antimalarial drugs. The
success of antimalarial treatment can be affected by the presence of drug-resistant …

The emergence of drug resistance continuously threatens global control of infectious
diseases, including malaria caused by the protozoan parasite Plasmodium falciparum. A …

In 8 malaria-endemic states in India, mixed Plasmodium spp. infections were detected by
PCR in 17.4%(265/1,521) of blood samples that microscopy had shown to contain only P …

Background Plasmodium falciparum resistance to series of anti-malarial drugs is a major
challenge in efforts to control and/or eliminate malaria globally. In 1998, following the …